Allelotype of 28 human breast cancer cell lines and xenografts

Por Harkes, I C, Elstrodt, F, Dinjens, W N M, Molier, M, Klijn, J G M, Berns, E M J J, Schutte, M
Publicado em 2003

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2

Por Schuyer, M, Burg, M E L van der, Henzen-Logmans, S C, Fieret, J H, Klijn, J G M, Look, M P, Foekens, J A, Stoter, G, Berns, E M J J
Publicado em 2001

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment

Por Beelen, K., Opdam, M., Severson, T. M., Koornstra, R. H. T., Vincent, A. D., Hauptmann, M., van Schaik, R. H. N., Berns, E. M. J. J., Vermorken, J. B., van Diest, P. J., Linn, S. C.
Publicado em 2013

The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer

Por Trinh, X B, Tjalma, W A A, Vermeulen, P B, Van den Eynden, G, Van der Auwera, I, Van Laere, S J, Helleman, J, Berns, E M J J, Dirix, L Y, van Dam, P A
Publicado em 2009

Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features

Por Berns, E M J J, Staveren, I L van, Verhoog, L, Ouweland, A M W van de, Gelder, M Meijer-van, Meijers-Heijboer, H, Portengen, H, Foekens, J A, Dorssers, L C J, Klijn, J G M
Publicado em 2001

High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer

Por Jansen, M. P. H. M., Reijm, E. A., Sieuwerts, A. M., Ruigrok-Ritstier, K., Look, M. P., Rodríguez-González, F. G., Heine, A. A. J., Martens, J. W., Sleijfer, S., Foekens, J. A., Berns, E. M. J. J.
Publicado em 2011